About Us
- About Us
- History & Facts
Products
- Overview
- Mental Health
  
  Tebonin®
  
  Vitango®
- Cough & Cold
  
  Kaloba®
  
  About Kaloba®
  
  Product Features
  
  The Kaloba® Quality Assurance
  
  The Umckaloabo® Foundation
  
  Kaloba® Accreditations
  
  Customer Endorsement
  
  Where can you find Kaloba® in Singapore
  
  Did you know?
- Others
  
  Prostakan®
  
  Venosan®
Events
Careers
Contact Us
Links
- Global Site
- web-BRAIN-nar

Schwabe's History
Our Tradition

1866

Dr. Willmar Schwabe founds the company in Leipzig.

1872

Dr. Schwabe's "Pharmacopoeia Homoeopathica Polyglottica" is published in several languages.

1878

Schwabe's first phytopharmaceutical product, "Schwabe's hamamelis ointment" today's Hametum® is launched.

1898

The first company abroad is founded in Amsterdam, the Netherlands.

1917

Pharmacist Dr. Willmar Schwabe II takes over the company management.

1926

Schwabe Pharmaceuticals moves to new premises in Leipzig, Germany

1935

The company management passes to Dr. Willmar Schwabe III, physician and pharmacist, and Dr. Wolfgang Schwabe, pharmacist and business executive.

1943

Crataegutt®, a phytomedicine for heart failure is launched.

1946

Schwabe Pharmaceuticals starts its operations in the new premises in Karlsruhe-Durlach.

1961

The Deutsche Homöopathie-Union (German Homoeopathic Union, DHU) company is founded, manufacturing and distributing homoeopathic medicines, while the Schwabe parent company concentrates all its Research and Development activities on allopathic phytomedicines.

1965

Tebonin®, the first Ginkgo biloba drug, is launched in Germany.

1975

Venoplant® retard is introduced to the German market.

1976

Biochemist Dr. Klaus-Peter Schwabe becomes managing director.

1977

Business executive Dr. Wolf-Dietrich Schwabe becomes managing director.

1980

The Schwabe group enters the Mexican market via the company Farmasa.

1982

Tebonin® forte is launched.

1983

Crataegutt® novo is introduced in Germany as a treatment for decreasing heart performance.

1985

In Germany, Spitzner Pharmaceuticals is acquired.

1985 - 1991

The company sets up its own Ginkgo plantations in France and United States.

Further companies are purchased in Italy, Switzerland, Spain, Germany and the US.

1992

The Schwabe Pharma AG is founded in Switzerland.

Schwabe enters the US herbal medicine market via Nature’s Way, Inc…

1994

In India Dr. Willmar Schwabe India Pvt. Ltd is founded.

In Austria the Austroplant Arzneimittel Gmbh starts business.

1996 - 1999

Schwabe-Wenex International starts operations in Hongkong.

Schwabe’s representative office in Moscow, Russia is founded.

2000 - 2003

Schwabe enters the Czech, Slovakian and Hungarian market via own subsidiaries of ASI.

2005

In Singapore, Schwabe Pharma Asia Pacific Pte. Ltd. starts operations.

2006

Abkit Inc. USA is purchased.

2008

Schwabe acquires MH Pharma UK.

Enzymatic Therapy Inc is purchased.

2009

Schwabe acquires Dr. Peithner Holding GmbH, Vienna, Austria

2010

In September 2010 Lasea® is launched in the German market.

2016

Olaf Schwabe, fifth-generation CEO

Since 1 May 2016, Olaf Schwabe has been the head of the Schwabe Group, representing the fifth generation of the family. As the chief executive officer, he is one of the five-member Group Executive Team which is responsible for business operations at the Schwabe Group and defines their global strategy.

By late 2016, the Schwabe Group had achieved sales of €900 million. The Schwabe Group currently employs around 3,600 people worldwide.

Schwabe's History Our Tradition